15% OFF YOUR FIRST ORDER · CODE 1stOrder
Research hub

PTD-DBM Peptide

PTD-DBM is a synthetic competitor peptide that interferes with the CXXC5–Dishevelled interaction and is used in preclinical research investigating Wnt/β-catenin signaling.

Synthetic fusion peptideprotein transduction domain peptideDishevelled-binding motif peptidecell-penetrating peptideCXXC5–Dishevelled interaction competitorWnt/β-catenin pathway modulator
Molecular Weight
3082.68 g/mol
Molecular Formula
C124H225N61O28S2
CAS Number
1609454-11-6
Purity
98.6%
Available nowPTD-DBM Peptide · in stock, EU dispatch
PTD-DBM and GHK-Cu Peptide Stack
1 mg
$37.80View
PTD-DBM Nasal Spray
99.69%
Price range: $35.30 through $64.35View
PTD-DBM Peptide Vial
1mg
Price range: $25.30 through $36.53View
PTD-DBM Pre Mixed Peptide 1mg
Pen Kit, 1 Cartridge, 2 Cartridges, 3 Cartridges
Price range: $26.84 through $72.46View
01

What Is PTD-DBM Peptide?

PTD-DBM is a synthetic peptide composed of a protein transduction domain, linker, and Dishevelled-binding motif. The peptide was developed as a molecular research tool based on these functional peptide components.

Its name reflects its structurePTD refers to the protein transduction domain, while DBM refers to the Dishevelled-binding motif. This defines PTD-DBM as a designed peptide construct rather than a naturally occurring peptide.
02

Research Overview Table

Research OverviewCurrent Status
Compound ClassSynthetic competitor peptide containing a protein transduction domain (PTD) and Dishevelled-binding motif (DBM)
Primary Research TargetCXXC5–Dishevelled (Dvl) protein interaction
Published Cell StudiesAvailable
Published Animal StudiesAvailable
Primary Research FieldWnt/β-catenin signaling and CXXC5–Dishevelled biology
Research MaturityPreclinical
Intended UseLaboratory research only
03

Chemical and Molecular Characteristics

Chemical NameProtein transduction domain–Dishevelled-binding motif peptide (PTD-DBM)
Compound NamePTD-DBM
Compound TypeSynthetic peptide
Molecular FormulaC124H225N61O28S2
Molecular Weight3,082.6 g/mol
Purity98.6%
CAS Number1609454-11-6
Batch/Lot Number20260816051
Primary Research TargetCXXC5–Dishevelled (Dvl) protein–protein interaction
Product Format(s)Lyophilized vials, nasal sprays, or pre-mixed injection pen
Physical PresentationSupplied as sterile lyophilized powder or pre-formulated liquid, depending on the selected product format

Certificates:

CoAhttps://iceland.direct-sarms.com/wp-content/uploads/2026/09/PTD-DBM_COA.pdf
HPLChttps://iceland.direct-sarms.com/wp-content/uploads/2026/09/PTD-DBM_HPLC.pdf
04

Mechanism of Action Under Investigation

PTD-DBM interferes with the CXXC5–Dishevelled (Dvl) protein interaction. The peptide contains the Dishevelled-binding motif used by CXXC5 and acts as a competitor, disrupting formation of the CXXC5–Dvl complex. This interaction is involved in CXXC5-mediated negative regulation of Wnt/β-catenin signaling.

Disruption of the CXXC5–Dvl interaction with PTD-DBM was associated in published experiments with increased β-catenin signaling, including increased nuclear β-catenin and Wnt reporter activity. The studies support this interaction as the basis of PTD-DBM activity, while the complete downstream molecular mechanism remains incompletely defined.

05

Scientific Research Context

PTD-DBM appears in the scientific literature as an experimental peptide for studying CXXC5-related Wnt/β-catenin regulation. Investigators have used cultured cells, ex vivo tissue preparations and mouse models to examine its biological activity in areas such as cutaneous biology, osteoblast differentiation, and hair-follicle biology. The available findings come primarily from in vitro and preclinical animal models.

06

PTD-DBM Biology and Biological Pathways

01

Primary Biological Function

CXXC5 functions as a negative-feedback regulator of Wnt/β-catenin signaling. Published studies show that Wnt signaling induces CXXC5, which then limits pathway activity through its interaction with Dishevelled. This regulatory role has been examined particularly in osteoblast differentiation and cutaneous biology.

02

Relevant Metabolic or Signaling Pathways

The primary pathway associated with CXXC5 biology is the canonical Wnt/β-catenin pathway. Published studies examined pathway activity through β-catenin levels, nuclear localization and Wnt reporter assays. Researchers also examined this pathway in processes such as osteoblast differentiation and hair-follicle biology.

03

Tissue-Specific Biology

Researchers have examined CXXC5-related biology in skin, bone and hair follicles. In skin, researchers have studied CXXC5 in epidermal keratinocytes and dermal fibroblasts during cutaneous wound studies. In bone, investigators examined its role during osteoblast differentiation. In hair follicles, studies identified CXXC5 in dermal papilla cells and arrector pili muscle and examined its relationship with follicular Wnt/β-catenin activity.

04

Experimental Biomarkers

Reported readouts include β-catenin, alkaline phosphatase (ALP), proliferating cell nuclear antigen (PCNA), collagen I, α-SMA, endothelin-1, Fgf18 and selected Wnt reporter activity. Nuclear β-catenin and pathway reporter activity have been used to assess Wnt/β-catenin signaling, while other markers provide context for specific cellular processes examined in individual studies.

05

Laboratory Investigation Methods

Published PTD-DBM experiments used Western blotting, RT-PCR, immunocytochemistry, Wnt reporter assays and immunoprecipitation. Researchers used these methods to measure protein expression, gene expression, β-catenin localization, pathway activity, and protein–protein interactions. The studies also used collagen assays and cell-based functional assays to examine related cellular responses.

07

Experimental Models Used in Published Research

01

Cell-Based Models

PTD-DBM studies used human dermal fibroblasts and HaCaT keratinocytes. These cultures provide defined cellular systems, but they cannot reproduce the full organization and cell-to-cell interactions of intact skin.

02

Ex Vivo Tissue Models

Researchers maintained mouse vibrissa hair follicles outside the animal for PTD-DBM experiments. The isolated follicles retain their local structure, but the preparation excludes surrounding skin, circulation and other whole-body influences.

03

Mouse Models

The published work includes full-thickness cutaneous wound models, hair-regrowth models, and wound-induced hair-follicle neogenesis models. Their main limitation is the biological difference between mouse and human skin and hair follicles, which limits direct translation to human biology.

08

PTD-DBM Published Scientific Research

01

Cutaneous Wound Healing

The published literature has examined PTD-DBM in cutaneous wound healing, with particular attention to CXXC5 regulation in dermal fibroblasts, collagen production and wound-associated Wnt/β-catenin activity.

02

Hair Regrowth and Wound-Induced Hair Neogenesis

Another research area concerns hair regrowth and wound induced hair-follicle neogenesis. The work examined PTD-DBM in relation to CXXC5, Dishevelled and Wnt/β-catenin activity during these regenerative processes.

03

PGD₂-Associated Hair Biology

A later study examined PTD-DBM in PGD₂-associated hair loss, including the relationship among DHT, PGD₂, CXXC5 and Wnt/β-catenin signaling. The study also investigated PTD-DBM in wound-induced hair neogenesis.

04

Cutaneous Tumor Biology

More recent research investigated PTD-DBM in cutaneous squamous cell carcinoma models, examining cellular behavior and whether PTD-DBM altered tumor associated phenotypes or DMBA/TPA-induced skin tumor development.

09

Limitations of Current Research

01

Evidence Is Predominantly Preclinical

The direct PTD-DBM literature remains preclinical. Current publications provide experimental findings but do not establish clinical efficacy or safety. The available evidence is therefore insufficient to draw conclusions about biological effects in humans.

02

Human Clinical Evidence

We identified no controlled human clinical trials of PTD-DBM in the reviewed literature. Human tissue has appeared in research involving CXXC5. But this does not provide controlled clinical evidence for PTD-DBM. Human pharmacokinetic and clinical safety data remain unavailable.

03

Species Differences

The available evidence cannot establish that PTD-DBM produces the same biological responses across species. Differences between human and mouse skin and hair biology create uncertainty when interpreting animal research findings in relation to human biology.

04

Study Design Limitations

The published investigations address different biological questions and use different experimental endpoints. Some work also combines PTD-DBM with other pathway modulating agents, making it difficult to attribute every observed response specifically to PTD-DBM.

05

Independent Replication

Direct PTD-DBM research remains limited to a small number of publications. Independent replication by unrelated research groups would provide stronger support for the reproducibility of the reported findings and help determine whether they remain consistent across research settings.

06

Long-Term Evidence

Long-term information remains limited. The published studies do not adequately characterize prolonged exposure, repeated experimental use or long-term biological responses in humans. As a result, the longer-term profile of PTD-DBM remains insufficiently defined.

10

Analytical Documentation

HPLC can separate the principal peptide from related impurities and provide a chromatographic purity profile. LC-MS adds molecular mass information that can support identity confirmation and help detect mass-related impurities. NMR may provide complementary structural information when the peptide and sample quantity are suitable for this analysis.

A Certificate of Analysis records the analytical results assigned to a particular batch. Depending on the testing scope, it may include purity, identity, and other measured quality attributes. Using analytical data alongside a batch specific CoA helps researchers assess material consistency before an experiment and identify results that impurities or degradation may affect.

Analytical documentation verifies product identity and quality, not biological performance.

11

Storage and Laboratory Handling

Store PTD-DBM at 2–8°C, following the storage condition stated on the product documentation. Keep the material under the specified conditions during laboratory storage and avoid unnecessary exposure to conditions that may affect the peptide.

Handle PTD-DBM using appropriate laboratory practices and by qualified personnel. Prevent contamination during handling and keep the material appropriately contained when not in use.

12

Why Researchers Choose Direct SARMs?

Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.

Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.

Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.

13

Frequently asked questions

PTD-DBM is a synthetic competitor peptide designed to interfere with the CXXC5–Dishevelled (Dvl) protein interaction. The published studies describe it as a protein transduction domain–fused Dishevelled-binding motif peptide and investigate it mainly in relation to CXXC5 and Wnt/β-catenin signaling.
14

Why choose us?

Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.

Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.

Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.

PTD-DBM Peptide is supplied solely for laboratory research and analytical purposes. It is not intended for human or veterinary use, consumption, diagnosis, treatment, or any clinical application. Information provided on this page is for scientific reference only and should be considered alongside the cited primary literature and relevant analytical documentation.
Available now

PTD-DBM Peptide from Direct Sarms Iceland

PTD-DBM Nasal Spray
99.69%
Price range: $35.30 through $64.35View
PTD-DBM Peptide Vial
1mg
Price range: $25.30 through $36.53View
PTD-DBM Pre Mixed Peptide 1mg
Pen Kit, 1 Cartridge, 2 Cartridges, 3 Cartridges
Price range: $26.84 through $72.46View